Antitumour ether lipids: proapoptotic agents with multiple therapeutic indications
- 19 April 2007
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 17 (4) , 385-405
- https://doi.org/10.1517/13543776.17.4.385
Abstract
(2007). Antitumour ether lipids: proapoptotic agents with multiple therapeutic indications. Expert Opinion on Therapeutic Patents: Vol. 17, No. 4, pp. 385-405. doi: 10.1517/13543776.17.4.385This publication has 128 references indexed in Scilit:
- Submicromolar doses of alkyl‐lysophospholipids induce rapid internalization, but not activation, of epidermal growth factor receptor and concomitant MAPK/ERK activation in A431 cellsInternational Journal of Cancer, 2002
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- D-21266, a new heterocyclic alkylphospholipid with antitumour activityEuropean Journal Of Cancer, 1997
- Molecular and cellular effects of hexadecylphosphocholine (miltefosine) in human myeloid leukaemic cell linesEuropean Journal Of Cancer, 1994
- Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancerEuropean Journal Of Cancer, 1993
- Phase II study of oral miltefosine in patients with squamous cell head and neck cancerEuropean Journal Of Cancer, 1993
- Phase II study of miltefosine (Hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult— An EORTC Soft Tissue and Bone Sarcoma Group studyEuropean Journal Of Cancer, 1993
- Early and Selective Induction of Apoptosis in Human Leukemic Cells by the Alkyl-Lysophospholipid ET-18-OCH3Biochemical and Biophysical Research Communications, 1993
- A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumoursZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Alkyllysophospholipid prevents induction of experimental allergic encephalomyelitisJournal of Autoimmunity, 1992